Groupe la Francaise Grows Stock Holdings in Merck & Co., Inc. $MRK

Groupe la Francaise boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 254.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 260,892 shares of the company’s stock after acquiring an additional 187,341 shares during the period. Groupe la Francaise’s holdings in Merck & Co., Inc. were worth $33,528,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. Graney & King LLC lifted its holdings in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. in the 4th quarter valued at $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Up 0.0%

NYSE:MRK opened at $150.37 on Monday. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a fifty day moving average price of $134.64 and a two-hundred day moving average price of $123.53. The stock has a market capitalization of $370.99 billion, a price-to-earnings ratio of 120.30, a PEG ratio of 6.54 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the firm earned $2.13 EPS. The business’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Insider Activity

In other news, EVP David Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares in the company, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. Insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MRK. Wolfe Research boosted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday, August 25th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research note on Wednesday, August 12th. Royal Bank Of Canada cut shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price target for the stock from $142.00 to $150.00 in a report on Thursday, August 20th. Finally, BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $148.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.